Over the next six months, 1,200 people from the ages of two to 45 will be recruited for the trial in four public hospitals here.

They will be divided into three groups according to their age - children, adolescents and adults - and will include a control group that will be administered another vaccine.

The study will then compare the safety of the dengue vaccine and the measure of immune response to it and compare it to the other vaccines - hepatitis A and flu vaccines.

Sanofi Pasteur, a unit of the French drug company Sanofi Aventis, has already tested the first dose of the vaccine on 1,200 people worldwide and is planning to test on another 5,000 in Asia, which includes Singapore.